Head-to-head evidence
ALN-5288 vs Diranersen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: MAPT mRNA (RNAi/ASO) · full Alzheimer's Disease pipeline
ALN-5288
Developed by Alnylam Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2030 · NCT07214727 (registry estimate)
Diranersen
Developed by Ionis Pharmaceuticals and partners
NCT03186989 · Phase 1 · completed
This dose-escalation study randomized participants to diranersen or placebo with both participants and staff blinded, but its primary endpoint was safety and tolerability rather than a cognitive or clinical outcome, which limits what it can show about therapeutic effect.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALN-5288's landscape · Diranersen's landscape